Universal receptive system as a novel regulator of transcriptomic activity of Staphylococcus aureus.
George Tetz, Kristina Kardava, Maria Vecherkovskaya...
https://pubmed.ncbi.nlm.nih.gov/39754239/Actively Recruiting
Led by Second Life Therapeutics · Updated on 2026-09-15
60
Participants Needed
3
Research Sites
8 weeks
Total Duration
Researchers are studying SL-28, an allogeneic, non-genetically modified cell-based therapy, for treating advanced solid tumors in patients who have not responded to previous chemotherapy or immunotherapies. This open-label, multi-center trial includes a Phase 1 dose escalation to identify safe and effective doses and Phase 2 expansion cohorts. The study targets adults with a range of advanced solid tumors, including head and neck, lung, gastrointestinal, genitourinary, gynecologic cancers, breast cancer, and melanoma. Participants receive SL-28 intravenously once daily, five days a week for 12 weeks. The trial starts with a low dose group monitored for 12 weeks, after which higher dose groups may be enrolled to determine the highest safe dose without severe side effects. The study evaluates SL-28 as a single-agent therapy with dose escalation across up to three cohorts. During the study, participants undergo safety monitoring including assessments of adverse events, vital signs, ECG changes, and dose-limiting toxicities over 12 weeks. Researchers also measure anti-tumor responses using RECIST criteria. Participants are evaluated for organ function and performance status. The total involvement includes treatment and observation periods to assess safety, pharmacokinetics, and preliminary efficacy of SL-28.
CONDITIONS
SL-28 for Advanced Solid Tumours
G
George Tetz, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Second Life Therapeutics
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment
Duration - 12 weeks
Participants receive SL-28 intravenously once daily for five days each week over 12 weeks. Dose levels may increase after safety monitoring to find the highest safe dose.
Daily dosing 5 days per week with regular safety monitoring visits
Duration - 12 weeks
After treatment, participants are monitored for safety and tumor response through clinical assessments and imaging over 12 weeks.
Periodic visits for safety and efficacy evaluations
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
George Tetz, Kristina Kardava, Maria Vecherkovskaya...
https://pubmed.ncbi.nlm.nih.gov/39754239/Victor Tetz, Kristina Kardava, Olzhas Shulenbayev...
https://pubmed.ncbi.nlm.nih.gov/41185720/Victor Tetz, Kristina Kardava, Olzhas Shulenbayev...
https://pubmed.ncbi.nlm.nih.gov/41347084/Victor Tetz, Kristina Kardava, Maria Vecherkovskaya...
https://pubmed.ncbi.nlm.nih.gov/39896476/Victor Tetz, Kristina Kardava, Maria Vecherkovskaya...
https://pubmed.ncbi.nlm.nih.gov/40578310/Victor Tetz, George Tetz
https://pubmed.ncbi.nlm.nih.gov/36195904/Second Life Therapeutics
Lead Sponsor